stockrowICON PLC
ICLR Healthcare Diagnostics & Research
ICON PLC’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.76% from fiscal 2024.
- Revenue
- −2.86%
- EPS
- +143.2%
- Free cash flow
- −8.01%
- Total debt
- −0.86%
Quarter to September 2026, against a year earlier
Follow ICLR
Alert me
ICON PLC (ICLR) Return on assets
ICON PLC's return on assets over the twelve months to 30 September 2026 was 2.74%, up 1.4 percentage points from fiscal 2025 (1.39%). Over the past ten years it has ranged from 1.39% (fiscal 2025) to 14.8% (fiscal 2016) — the current reading is the lowest in ten years. That is above the Diagnostics & Research industry median of −6.05% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 1.39% | (3.01) |
| FY2024 | 4.40% | 0.82 |
| FY2023 | 3.58% | 0.66 |
| FY2022 | 2.92% | 1.45 |
| FY2021 | 1.47% | (9.01) |
| FY2020 | 10.5% | (3.74) |
| FY2019 | 14.2% | (0.12) |
| FY2018 | 14.3% | 0.17 |
| FY2017 | 14.2% | (0.63) |
| FY2016 | 14.8% | 0.04 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| MEDP Medpace Holdings, Inc. compare | 25.5% |
| ILMN Illumina, Inc. compare | 13.8% |
| QGEN QIAGEN N.V. compare | 6.99% |
| DGX Quest Diagnostics Incorporated compare | 6.73% |
| LH Labcorp Holdings Inc. compare | 5.40% |
| ICLR ICON PLC | 2.74% |
| RVTY Revvity Inc. compare | 2.14% |
| CRL Charles River Laboratories International, Inc. compare | 0.54% |
| GH Guardant Health, Inc. compare | −30.7% |
| Diagnostics & Research industry median | −6.05% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on ICLR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement